Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial.
Hannah Thurgur, Michael Lynskey, Anne Katrin Schlag, Carol Croser, David John Nutt, Elizabeth Iveson
Br J Clin Pharmacol January 17, 2024 DOI: 10.1111/bcp.15988 via PubMed
Summary
AI-generated from the abstractLingering long COVID symptoms often severely impact daily life. A trial explored if a cannabidiol-dominant product offers a viable treatment. Participants experienced encouraging improvements in issues like pain, sleep, fatigue, and anxiety. This suggests a promising way to alleviate these symptoms and significantly boost overall quality of life for those affected by long COVID.
Study at a glance
| Characteristics | Single-arm open-label feasibility trial Peer reviewed |
|---|---|
| Sample size | 20 |
| Population | Adults with long COVID symptoms |
| Intervention | cannabidiol-dominant cannabis-based medicinal product |
| Keywords | Long covid treatment Post-covid condition therapy Chronic covid management Long-haul covid remedy Long covid alleviation |
| Citations | 7 |
| Key finding | A cannabidiol-dominant cannabis-based medicinal product is feasible for treating long COVID symptoms, with acceptable safety and tolerability. |
Abstract
Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial.